Bietti Crystalline Dystrophy

👪

Inheritance

1

Autosomal recessive HP:0000007

Biallelic CYP4V2 variants are detected in essentially all molecularly solved patients - 98.3% of families in a cohort of 175 Chinese families - making this one of the least genetically heterogeneous inherited retinal dystrophies.

Autosomal recessive inheritance

Show evidence (1 reference)

PMID:37584790 SUPPORT Human Clinical

"Molecular screening detected biallelic CYP4V2 pathogenic variants in 98.3% (172/175) of the families, including 19 novel ones."

Quantifies the diagnostic yield of biallelic CYP4V2 testing in a large cohort, supporting both the recessive inheritance and the near-monogenic character of the disease.

?

Discussions and Knowledge Gaps

1

Are ER stress and ferroptosis two independent routes from PUFA overload to RPE death in Bietti crystalline dystrophy, or two readouts of one process, and which should a non-gene-therapy intervention target?

KNOWLEDGE GAP bcd_ferroptosis_versus_er_stress_dominance

Attached to

pathophysiology#ER Stress and Mitochondrial Dysfunction pathophysiology#Iron-Dependent Lipid Peroxidation and Ferroptosis

Both arms are supported by rescue experiments in CYP4V2-deficient RPE - IRE1-alpha inhibition restores mitochondrial potential and ATP, iron chelation suppresses ferroptosis and restores retinal function in vivo - and both converge on mitochondrial dysfunction and oxidative stress, so the experiments as performed cannot distinguish two parallel routes from one route measured two ways. This matters because the arms imply different drugs. If they are sequential, only the upstream one is worth targeting; if parallel, blocking one leaves the other running, and the single-agent rescues reported so far would be hard to explain.

Proposed experiments

Epistasis between IRE1-alpha inhibition and iron chelation in CYP4V2-null RPE

bcd_combined_ire1_iron_epistasis

Apply IRE1-alpha inhibition and deferiprone alone and in combination to CYP4V2-knockout RPE under matched PUFA load, measuring lipid peroxidation, ERO1-L-alpha induction, mitochondrial membrane potential and viability. A non-additive combination indicates one pathway; additive or synergistic rescue indicates two, and identifies which single agent leaves more residual death.

⚙

Pathophysiology

6

CYP4V2 Loss of Function

Biallelic loss-of-function variants abolish CYP4V2, a cytochrome P450 enzyme that omega-hydroxylates fatty acids. In East Asian cohorts the spectrum is dominated by a single founder splice-region allele, c.802-8_810del17insGC, which accounts for over half of disease alleles - a concentration that makes targeted testing efficient and gene-replacement trials feasible to recruit for.

retinal pigment epithelial cell CL:0002586

Fatty acid omega-oxidation GO:0010430 ↓ DECREASED

Downstream

Polyunsaturated Fatty Acid Overload in the Retinal Pigment Epithelium

Show evidence (2 references)

PMID:42123783 SUPPORT In Vitro

"Bietti crystalline dystrophy (BCD) is a hereditary retinal disease caused by loss-of-function mutations in the CYP4V2 gene."

Assigns causation to CYP4V2 loss of function; the same study measures the enzyme's activity as omega-hydroxylation of lauric acid, which is the catalytic function this node asserts is lost.

PMID:37584790 SUPPORT Human Clinical

"The most frequent pathogenic variant was c.802-8_810del17insGC, with the allele frequency of 55.7% (195/350), followed by c.992A>C (28/350, 8%) and c.1091-2A>G (23/350, 6.6%)."

Quantifies the founder allele's dominance of the mutational spectrum in this population, supporting the claim made in this node's description.

Polyunsaturated Fatty Acid Overload in the Retinal Pigment Epithelium

Without CYP4V2 the retinal pigment epithelium cannot dispose of fatty acids through the omega-oxidation route, and polyunsaturated species accumulate. This is measurable rather than inferred: lipid profiling of RPE from Cyp4v3-null mice - the murine orthologue - shows increased eicosapentaenoic and arachidonic acid. The RPE is the cell that suffers because it phagocytoses a daily load of PUFA-rich photoreceptor outer-segment membrane, so it carries by far the highest flux through this pathway of any cell in the body. Dietary fat load worsens the phenotype in the model, which is consistent with substrate supply driving the disease.

retinal pigment epithelial cell CL:0002586

Lipid homeostasis GO:0055088 ⚠ ABNORMAL

pigmented layer of retina UBERON:0001782

Downstream

ER Stress and Mitochondrial Dysfunction

Iron-Dependent Lipid Peroxidation and Ferroptosis

Show evidence (2 references)

PMID:38992691 SUPPORT Model Organism

"Increased levels of PUFAs, such as EPA (C22:5) and AA (C20:4), were observed in the RPE of Cyp4v3 KO mice."

Direct lipidomic measurement of the accumulation this node asserts, in the correct cell type and in an orthologous knockout.

PMID:38992691 SUPPORT Model Organism

"Cyp4v3 KO mice exhibited progressive retinal degeneration and lipid accumulation, similar to the BCD phenotype, which was exacerbated by a high-fat diet (HFD)."

Supports the substrate-supply claim: increasing dietary fat worsens the phenotype, which is what would be expected if accumulation of the unmetabolized substrate drives the degeneration.

ER Stress and Mitochondrial Dysfunction

One of two demonstrated routes from lipid overload to RPE death. Proteomic profiling of CYP4V2-knockdown RPE identifies endoplasmic reticulum stress as the most enriched pathway; IRE1-alpha signalling drives up the ER oxidoreductase ERO1-L-alpha, generating ER-associated oxidative stress, and mitochondrial transmembrane potential and ATP production fall. That IRE1-alpha inhibition reverses both the ERO1-L-alpha induction and the mitochondrial deficits establishes the arm as causal rather than correlative.

retinal pigment epithelial cell CL:0002586

Response to endoplasmic reticulum stress GO:0034976 ↑ INCREASED Response to oxidative stress GO:0006979 ↑ INCREASED

Downstream

Progressive RPE and Chorioretinal Atrophy

Show evidence (2 references)

PMID:40466971 SUPPORT In Vitro

"Inositol-requiring enzyme 1 α (IRE1α) inhibitors suppressed upregulation of endoplasmic reticulum oxidoreductase 1 alpha (ERO1-Lα) protein expression, which contributed to ER-associated oxidative stress."

Establishes the IRE1-alpha to ERO1-L-alpha to oxidative stress sequence this node asserts, with pharmacological inhibition demonstrating direction.

PMID:40466971 SUPPORT In Vitro

"Loss of mitochondrial transmembrane potential and reduced ATP production were mitigated with IRE1α inhibitor in CYP4V2-KD ARPE-19 cells."

Shows the mitochondrial failure is downstream of the ER stress arm, since blocking IRE1-alpha rescues it.

Iron-Dependent Lipid Peroxidation and Ferroptosis

The second demonstrated route, and the one that most directly explains why a PUFA-handling defect is lethal to the cell: polyunsaturated fatty acids are the preferred substrate of the lipid peroxidation that executes ferroptosis. Cyp4v3-null RPE shows lipid peroxidation, reactive oxygen species accumulation, mitochondrial defects and upregulation of ferroptosis genes, together with upregulation of NCOA4 - the ferritinophagy receptor - and abnormal accumulation of ferrous iron. Iron chelation with deferiprone suppresses the phenotype in vitro and restores retinal function and morphology in the knockout mouse, which makes this arm both causal and druggable.

retinal pigment epithelial cell CL:0002586

Ferroptosis GO:0097707 ↑ INCREASED Intracellular iron ion homeostasis GO:0006879 ⚠ ABNORMAL

Downstream

Progressive RPE and Chorioretinal Atrophy

Show evidence (2 references)

PMID:38992691 SUPPORT Model Organism

"Ferroptosis-related characteristics, including mitochondrial defects, lipid peroxidation, ROS accumulation, and upregulation of related genes, were detected in the RPE both in vitro and in vivo."

Documents the ferroptotic signature in the correct cell type, in both cellular and animal models.

PMID:38992691 SUPPORT Model Organism

"Transcriptome analysis of RPE in Cyp4v3 KO mice revealed changes in genes involved in iron homeostasis, particularly an upregulation of NCOA4, which was confirmed by immunofluorescence."

Supports the iron arm specifically, identifying the ferritinophagy receptor whose induction accompanies the ferrous iron accumulation.

Progressive RPE and Chorioretinal Atrophy

Both arms converge on death of the retinal pigment epithelium, followed by loss of the choriocapillaris it supports and of the photoreceptors that depend on it. Atrophy spreads through the posterior pole and, as it does, the crystalline deposits that gave the disease its name progressively disappear - which is why crystal count is a poor progression marker and RPE atrophy area is the meaningful one. Two clinical distributions are recognized: a peripheral type and a central type, the latter with worse central acuity but better preserved overall retinal function.

retinal pigment epithelial cell CL:0002586 photoreceptor cell CL:0000210

Photoreceptor cell maintenance GO:0045494 ↓ DECREASED

pigmented layer of retina UBERON:0001782 optic choroid UBERON:0001776

Downstream

Progressive Visual Loss After the Fourth Decade

Show evidence (2 references)

PMID:38992691 SUPPORT Model Organism

"PUFAs resulting from CYP4V2 mutation may serve as substrates for ferroptosis, potentially working in conjunction with NCOA4-regulated iron accumulation, ultimately leading to RPE degeneration."

States the authors' proposed causal chain ending in RPE degeneration, which is the endpoint this node models.

PMID:37584790 SUPPORT Human Clinical

"Two clinical types were observed: peripheral type (type P) and central type (type C)."

Documents the two clinical distributions of atrophy described in this node.

Progressive Visual Loss After the Fourth Decade

Vision is comparatively well preserved through early adult life and then declines, with a significant fall in best-corrected acuity in patients over 40 in a cohort of 208. Genotype modulates the timing: patients carrying the founder splice allele in trans with a truncating variant reach severe visual impairment younger than those homozygous for the founder allele, consistent with the founder allele being hypomorphic rather than null. That relative preservation before 40 defines the therapeutic window for any disease-modifying intervention.

Visual perception GO:0007601 ↓ DECREASED

Show evidence (2 references)

PMID:37584790 SUPPORT Human Clinical

"A significant decline of BCVA was revealed in patients over 40 years old (P<0.001)."

Quantifies the age inflection in visual acuity that this node describes, in a 208-patient cohort.

PMID:37584790 SUPPORT Human Clinical

"BCR patients with IVS6-8/Tru had an earlier decline in visual acuity than those with homo IVS6-8."

Supports the genotype-timing relationship this node asserts, comparing the founder-plus-truncating genotype against founder homozygotes.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

4

Eye 2

Progressive Visual Loss VERY_FREQUENT HP:0000529

Show evidence (3 references)

PMID:37584790 SUPPORT Human Clinical

"A significant decline of BCVA was revealed in patients over 40 years old (P<0.001)."

Reports the measured decline in best-corrected visual acuity that this phenotype asserts. The previously quoted sentence from this cohort ("BCR patients preserved relatively good vision before 40 years old") states the opposite of the claim and is retained below only as the age qualifier it actually is.

PMID:37584790 SUPPORT Human Clinical

"BCR patients preserved relatively good vision before 40 years old."

Qualifies rather than supports the phenotype: it establishes that the loss is age-dependent and that vision is comparatively spared in the first four decades. Marked PARTIAL because it bounds the claim rather than evidencing it.

PMID:22497028 SUPPORT Other

"With time, loss of peripheral visual field, central acuity, or both result in legal blindness in most if not all affected individuals."

Upgrades the frequency justification from a Pattern D clinical estimate to a Pattern C mapping: GeneReviews' "most if not all" maps to VERY_FREQUENT under docs/frequency-evidence-guidelines.md. Evidence source is OTHER because GeneReviews is an expert-curated clinical synthesis.

Abnormal Retinal Pigmentation HP:0007703

Show evidence (1 reference)

PMID:38992691 SUPPORT Model Organism

"Cyp4v3 KO mice exhibited progressive retinal degeneration and lipid accumulation, similar to the BCD phenotype, which was exacerbated by a high-fat diet (HFD)."

Supports RPE involvement as the site of degeneration underlying the pigmentary abnormality.

Other 2

Retinal Crystals HP:0030507

Show evidence (2 references)

PMID:42123783 SUPPORT In Vitro

"Bietti crystalline dystrophy (BCD) is a hereditary retinal disease caused by loss-of-function mutations in the CYP4V2 gene."

Confirms the disease identity behind this eponymous crystalline phenotype. No frequency band is asserted because this citation does not quantify crystal prevalence.

PMID:22497028 SUPPORT Other

"Bietti crystalline dystrophy (BCD) is a chorioretinal degeneration characterized by the presence of yellow-white crystals and/or complex lipid deposits in the retina and (to a variable degree) the cornea."

GeneReviews adds a component this entry omitted: the crystalline deposits are not confined to the retina but variably involve the cornea as well, which is part of why the disease is also called Bietti crystalline CORNEOretinal dystrophy. Evidence source is OTHER because GeneReviews is an expert-curated clinical synthesis.

Chorioretinal Atrophy VERY_FREQUENT HP:0000533

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:38992691 SUPPORT Model Organism

"Bietti crystalline dystrophy (BCD) is an inherited retinal degeneration disease caused by mutations in the CYP4V2 gene."

Establishes retinal degeneration as the defining process of the disease. VERY_FREQUENT is a Pattern C mapping of that definitional framing (docs/frequency-evidence-guidelines.md); no proportion is reported.

🧬

Genetic Associations

1

CYP4V2 (Biallelic loss-of-function variants)

Gene: CYP4V2 hgnc:23198 relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:37584790 SUPPORT Human Clinical

"Molecular screening detected biallelic CYP4V2 pathogenic variants in 98.3% (172/175) of the families, including 19 novel ones."

Establishes CYP4V2 as effectively the sole disease gene, with a diagnostic yield near 100% in a large cohort.

💊

Medical Actions

2

Iron Chelation (Deferiprone, Preclinical)

Action: Pharmacotherapy NCIT:C15986

Agent: deferiprone CHEBI:68554

Iron chelation targets the ferroptosis arm rather than the enzyme defect. Deferiprone suppressed the ferroptotic phenotype in CYP4V2-mutant RPE and, given orally, restored retinal function and morphology in Cyp4v3-null mice. This is preclinical only - there is no clinical therapy for Bietti crystalline dystrophy - but it is recorded because it is a mechanism-directed intervention with in vivo rescue, and because it acts on a node distinct from the one gene replacement acts on.

Mechanism Target:

INHIBITS Iron-Dependent Lipid Peroxidation and Ferroptosis — Chelating ferrous iron removes the catalyst of lipid peroxidation, acting on the ferroptosis arm specifically and leaving the upstream PUFA accumulation untouched.

Show evidence (1 reference)

PMID:38992691 SUPPORT Model Organism

"DFP, an iron chelator administration suppressed ferroptosis phenotype in CYP4V2 mutated RPE. Oral administration of DFP also restored the retinal function and morphology in Cyp4v3 KO mice."

Demonstrates target engagement in vitro and functional and structural rescue in vivo, establishing this node as a druggable target.

Show evidence (1 reference)

PMID:38992691 SUPPORT Model Organism

"Currently, there is no clinical therapy approach available for BCD patients."

States plainly that no clinical therapy exists. Marked PARTIAL because this treatment is supported only by preclinical rescue, not by human data.

rAAV-CYP4V2 Gene Replacement (Preclinical)

Action: gene therapy Ontology label: Gene Therapy NCIT:C15238

Recombinant AAV delivery of human CYP4V2 to restore omega-hydroxylase activity in the retinal pigment epithelium. Product-development work has established a quantitative LC-MS/MS potency assay measuring the enzyme's conversion of lauric acid to 12-hydroxylauric acid across AAV2, AAV8 and AAV2/8 serotypes - which is the kind of release assay a clinical programme requires. No human trial data. The near-monogenic genetics and the founder allele make this an unusually tractable gene-replacement target.

Mechanism Target:

RESTORES CYP4V2 Loss of Function — Vector-delivered CYP4V2 restores the missing omega-hydroxylase, acting on the trigger lesion upstream of both downstream arms.

Show evidence (1 reference)

PMID:42123783 SUPPORT In Vitro

"Gene replacement therapy using rAAV-hCYP4V2 represents a promising therapeutic strategy, requiring robust bioassays for product quality control."

Establishes the gene-replacement strategy and that it is at the product-characterization stage. Marked PARTIAL because this demonstrates restored enzyme activity in transduced cells, not clinical benefit.

Show evidence (1 reference)

PMID:42123783 SUPPORT INDIRECT In Vitro

"The method was successfully applied to three AAV serotypes (AAV2, AAV8, and AAV2/8), with all RSDs < 23.9%."

Documents the potency assay across candidate serotypes. Marked INDIRECT because this is manufacturing-stage evidence, not evidence of efficacy.

{ }

Source YAML

click to show

name: Bietti Crystalline Dystrophy
creation_date: "2026-08-22T00:00:00Z"
category: Mendelian
description: >
  Bietti crystalline dystrophy is an autosomal recessive retinal degeneration
  caused by biallelic loss-of-function variants in CYP4V2, a cytochrome P450
  fatty acid omega-hydroxylase. It is one of the commoner inherited retinal
  dystrophies in East Asian populations and is named for the glittering
  yellow-white crystalline deposits scattered through the posterior pole and, to
  a variable degree, the corneal limbus - hence the fuller name Bietti
  crystalline corneoretinal dystrophy. The crystals are nonetheless
  the least mechanistically informative part of the picture:
  they fade as the disease advances, and the destructive process is atrophy of
  the retinal pigment epithelium and choriocapillaris beneath them. Loss of
  CYP4V2 leaves the RPE unable to omega-hydroxylate polyunsaturated fatty acids,
  which accumulate. Two convergent routes downstream have been demonstrated in
  CYP4V2-deficient RPE: an endoplasmic reticulum stress arm in which IRE1-alpha
  signalling drives ERO1-L-alpha-dependent oxidative stress and mitochondrial
  failure, and a ferroptosis arm in which the accumulated PUFAs serve as
  peroxidation substrate alongside NCOA4-associated iron accumulation. Vision is
  relatively preserved before 40 and then declines. There is no approved
  therapy; iron chelation and rAAV-CYP4V2 gene replacement are both preclinical.
disease_term:
  preferred_term: Bietti crystalline corneoretinal dystrophy
  term:
    id: MONDO:0008865
    label: Bietti crystalline corneoretinal dystrophy
synonyms:
- Bietti crystalline dystrophy
- BCD
- Bietti crystalline retinopathy
- crystalline retinopathy
parents:
- Ophthalmological Disease
- Inherited retinal dystrophy
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    Biallelic CYP4V2 variants are detected in essentially all molecularly solved
    patients - 98.3% of families in a cohort of 175 Chinese families - making
    this one of the least genetically heterogeneous inherited retinal
    dystrophies.
  evidence:
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular screening detected biallelic CYP4V2 pathogenic variants in 98.3% (172/175) of the families, including 19 novel ones."
    explanation: >
      Quantifies the diagnostic yield of biallelic CYP4V2 testing in a large
      cohort, supporting both the recessive inheritance and the near-monogenic
      character of the disease.
pathophysiology:
- name: CYP4V2 Loss of Function
  description: >
    Biallelic loss-of-function variants abolish CYP4V2, a cytochrome P450
    enzyme that omega-hydroxylates fatty acids. In East Asian cohorts the
    spectrum is dominated by a single founder splice-region allele,
    c.802-8_810del17insGC, which accounts for over half of disease alleles - a
    concentration that makes targeted testing efficient and gene-replacement
    trials feasible to recruit for.
  role: trigger
  biological_scale: MOLECULAR
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: Fatty acid omega-oxidation
    term:
      id: GO:0010430
      label: fatty acid omega-oxidation
    modifier: DECREASED
  evidence:
  - reference: PMID:42123783
    reference_title: "Development and Validation of a Quantitative LC-MS/MS Method for Measuring CYP4V2 Enzyme Activity via 12-Hydroxylauric Acid in rAAV-hCYP4V2 Gene Therapy Products."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Bietti crystalline dystrophy (BCD) is a hereditary retinal disease caused by loss-of-function mutations in the CYP4V2 gene."
    explanation: >
      Assigns causation to CYP4V2 loss of function; the same study measures the
      enzyme's activity as omega-hydroxylation of lauric acid, which is the
      catalytic function this node asserts is lost.
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequent pathogenic variant was c.802-8_810del17insGC, with the allele frequency of 55.7% (195/350), followed by c.992A>C (28/350, 8%) and c.1091-2A>G (23/350, 6.6%)."
    explanation: >
      Quantifies the founder allele's dominance of the mutational spectrum in
      this population, supporting the claim made in this node's description.
  downstream:
  - target: Polyunsaturated Fatty Acid Overload in the Retinal Pigment Epithelium
    causal_link_type: DIRECT

- name: Polyunsaturated Fatty Acid Overload in the Retinal Pigment Epithelium
  description: >
    Without CYP4V2 the retinal pigment epithelium cannot dispose of fatty acids
    through the omega-oxidation route, and polyunsaturated species accumulate.
    This is measurable rather than inferred: lipid profiling of RPE from
    Cyp4v3-null mice - the murine orthologue - shows increased eicosapentaenoic
    and arachidonic acid. The RPE is the cell that suffers because it
    phagocytoses a daily load of PUFA-rich photoreceptor outer-segment membrane,
    so it carries by far the highest flux through this pathway of any cell in
    the body. Dietary fat load worsens the phenotype in the model, which is
    consistent with substrate supply driving the disease.
  role: central_effector
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: Lipid homeostasis
    term:
      id: GO:0055088
      label: lipid homeostasis
    modifier: ABNORMAL
  locations:
  - preferred_term: pigmented layer of retina
    term:
      id: UBERON:0001782
      label: pigmented layer of retina
  evidence:
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Increased levels of PUFAs, such as EPA (C22:5) and AA (C20:4), were observed in the RPE of Cyp4v3 KO mice."
    explanation: >
      Direct lipidomic measurement of the accumulation this node asserts, in the
      correct cell type and in an orthologous knockout.
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Cyp4v3 KO mice exhibited progressive retinal degeneration and lipid accumulation, similar to the BCD phenotype, which was exacerbated by a high-fat diet (HFD)."
    explanation: >
      Supports the substrate-supply claim: increasing dietary fat worsens the
      phenotype, which is what would be expected if accumulation of the
      unmetabolized substrate drives the degeneration.
  downstream:
  - target: ER Stress and Mitochondrial Dysfunction
    causal_link_type: DIRECT
  - target: Iron-Dependent Lipid Peroxidation and Ferroptosis
    causal_link_type: DIRECT

- name: ER Stress and Mitochondrial Dysfunction
  description: >
    One of two demonstrated routes from lipid overload to RPE death. Proteomic
    profiling of CYP4V2-knockdown RPE identifies endoplasmic reticulum stress as
    the most enriched pathway; IRE1-alpha signalling drives up the ER
    oxidoreductase ERO1-L-alpha, generating ER-associated oxidative stress, and
    mitochondrial transmembrane potential and ATP production fall. That IRE1-alpha
    inhibition reverses both the ERO1-L-alpha induction and the mitochondrial
    deficits establishes the arm as causal rather than correlative.
  role: effector
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: Response to endoplasmic reticulum stress
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
    modifier: INCREASED
  - preferred_term: Response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
    modifier: INCREASED
  evidence:
  - reference: PMID:40466971
    reference_title: "IRE1α-mediated endoplasmic reticulum stress response regulates oxidative damage in CYP4V2 deficient human retinal pigment epithelial cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Inositol-requiring enzyme 1 α (IRE1α) inhibitors suppressed upregulation of endoplasmic reticulum oxidoreductase 1 alpha (ERO1-Lα) protein expression, which contributed to ER-associated oxidative stress."
    explanation: >
      Establishes the IRE1-alpha to ERO1-L-alpha to oxidative stress sequence
      this node asserts, with pharmacological inhibition demonstrating direction.
  - reference: PMID:40466971
    reference_title: "IRE1α-mediated endoplasmic reticulum stress response regulates oxidative damage in CYP4V2 deficient human retinal pigment epithelial cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Loss of mitochondrial transmembrane potential and reduced ATP production were mitigated with IRE1α inhibitor in CYP4V2-KD ARPE-19 cells."
    explanation: >
      Shows the mitochondrial failure is downstream of the ER stress arm, since
      blocking IRE1-alpha rescues it.
  downstream:
  - target: Progressive RPE and Chorioretinal Atrophy
    causal_link_type: DIRECT

- name: Iron-Dependent Lipid Peroxidation and Ferroptosis
  description: >
    The second demonstrated route, and the one that most directly explains why a
    PUFA-handling defect is lethal to the cell: polyunsaturated fatty acids are
    the preferred substrate of the lipid peroxidation that executes ferroptosis.
    Cyp4v3-null RPE shows lipid peroxidation, reactive oxygen species
    accumulation, mitochondrial defects and upregulation of ferroptosis genes,
    together with upregulation of NCOA4 - the ferritinophagy receptor - and
    abnormal accumulation of ferrous iron. Iron chelation with deferiprone
    suppresses the phenotype in vitro and restores retinal function and
    morphology in the knockout mouse, which makes this arm both causal and
    druggable.
  role: effector
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  biological_processes:
  - preferred_term: Ferroptosis
    term:
      id: GO:0097707
      label: ferroptosis
    modifier: INCREASED
  - preferred_term: Intracellular iron ion homeostasis
    term:
      id: GO:0006879
      label: intracellular iron ion homeostasis
    modifier: ABNORMAL
  evidence:
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Ferroptosis-related characteristics, including mitochondrial defects, lipid peroxidation, ROS accumulation, and upregulation of related genes, were detected in the RPE both in vitro and in vivo."
    explanation: >
      Documents the ferroptotic signature in the correct cell type, in both
      cellular and animal models.
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Transcriptome analysis of RPE in Cyp4v3 KO mice revealed changes in genes involved in iron homeostasis, particularly an upregulation of NCOA4, which was confirmed by immunofluorescence."
    explanation: >
      Supports the iron arm specifically, identifying the ferritinophagy
      receptor whose induction accompanies the ferrous iron accumulation.
  downstream:
  - target: Progressive RPE and Chorioretinal Atrophy
    causal_link_type: DIRECT

- name: Progressive RPE and Chorioretinal Atrophy
  description: >
    Both arms converge on death of the retinal pigment epithelium, followed by
    loss of the choriocapillaris it supports and of the photoreceptors that
    depend on it. Atrophy spreads through the posterior pole and, as it does,
    the crystalline deposits that gave the disease its name progressively
    disappear - which is why crystal count is a poor progression marker and
    RPE atrophy area is the meaningful one. Two clinical distributions are
    recognized: a peripheral type and a central type, the latter with worse
    central acuity but better preserved overall retinal function.
  role: consequence
  biological_scale: TISSUE
  cell_types:
  - preferred_term: retinal pigment epithelial cell
    term:
      id: CL:0002586
      label: retinal pigment epithelial cell
  - preferred_term: photoreceptor cell
    term:
      id: CL:0000210
      label: photoreceptor cell
  biological_processes:
  - preferred_term: Photoreceptor cell maintenance
    term:
      id: GO:0045494
      label: photoreceptor cell maintenance
    modifier: DECREASED
  locations:
  - preferred_term: pigmented layer of retina
    term:
      id: UBERON:0001782
      label: pigmented layer of retina
  - preferred_term: optic choroid
    term:
      id: UBERON:0001776
      label: optic choroid
  conforms_to: "photoreceptor_degeneration#Rod Photoreceptor Apoptosis"
  evidence:
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "PUFAs resulting from CYP4V2 mutation may serve as substrates for ferroptosis, potentially working in conjunction with NCOA4-regulated iron accumulation, ultimately leading to RPE degeneration."
    explanation: >
      States the authors' proposed causal chain ending in RPE degeneration,
      which is the endpoint this node models.
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two clinical types were observed: peripheral type (type P) and central type (type C)."
    explanation: >
      Documents the two clinical distributions of atrophy described in this
      node.
  downstream:
  - target: Progressive Visual Loss After the Fourth Decade
    causal_link_type: DIRECT

- name: Progressive Visual Loss After the Fourth Decade
  description: >
    Vision is comparatively well preserved through early adult life and then
    declines, with a significant fall in best-corrected acuity in patients over
    40 in a cohort of 208. Genotype modulates the timing: patients carrying the
    founder splice allele in trans with a truncating variant reach severe visual
    impairment younger than those homozygous for the founder allele, consistent
    with the founder allele being hypomorphic rather than null. That relative
    preservation before 40 defines the therapeutic window for any
    disease-modifying intervention.
  role: consequence
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: Visual perception
    term:
      id: GO:0007601
      label: visual perception
    modifier: DECREASED
  evidence:
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant decline of BCVA was revealed in patients over 40 years old (P<0.001)."
    explanation: >
      Quantifies the age inflection in visual acuity that this node describes,
      in a 208-patient cohort.
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BCR patients with IVS6-8/Tru had an earlier decline in visual acuity than those with homo IVS6-8."
    explanation: >
      Supports the genotype-timing relationship this node asserts, comparing the
      founder-plus-truncating genotype against founder homozygotes.
phenotypes:
- category: Ocular
  name: Retinal Crystals
  description: >
    Glittering yellow-white crystalline deposits scattered through the posterior
    pole, the eponymous sign. They diminish as atrophy advances, so their
    absence in late disease does not exclude the diagnosis.
  phenotype_term:
    preferred_term: Retinal crystals
    term:
      id: HP:0030507
      label: Retinal crystals
  evidence:
  - reference: PMID:42123783
    reference_title: "Development and Validation of a Quantitative LC-MS/MS Method for Measuring CYP4V2 Enzyme Activity via 12-Hydroxylauric Acid in rAAV-hCYP4V2 Gene Therapy Products."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Bietti crystalline dystrophy (BCD) is a hereditary retinal disease caused by loss-of-function mutations in the CYP4V2 gene."
    explanation: >
      Confirms the disease identity behind this eponymous crystalline
      phenotype. No frequency band is asserted because this citation does not
      quantify crystal prevalence.
  - reference: PMID:22497028
    reference_title: "Bietti Crystalline Dystrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Bietti crystalline dystrophy (BCD) is a chorioretinal degeneration characterized by the presence of yellow-white crystals and/or complex lipid deposits in the retina and (to a variable degree) the cornea."
    explanation: >
      GeneReviews adds a component this entry omitted: the crystalline deposits
      are not confined to the retina but variably involve the cornea as well,
      which is part of why the disease is also called Bietti crystalline
      CORNEOretinal dystrophy. Evidence source is OTHER because GeneReviews is
      an expert-curated clinical synthesis.
- category: Ocular
  name: Chorioretinal Atrophy
  description: >
    Progressive atrophy of retinal pigment epithelium and choriocapillaris in
    the posterior pole, the destructive lesion of the disease and the meaningful
    progression marker.
  phenotype_term:
    preferred_term: Chorioretinal atrophy
    term:
      id: HP:0000533
      label: Chorioretinal atrophy
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Bietti crystalline dystrophy (BCD) is an inherited retinal degeneration disease caused by mutations in the CYP4V2 gene."
    explanation: >
      Establishes retinal degeneration as the defining process of the disease.
      VERY_FREQUENT is a Pattern C mapping of that definitional framing
      (docs/frequency-evidence-guidelines.md); no proportion is reported.
- category: Ocular
  name: Progressive Visual Loss
  description: >
    Decline in best-corrected visual acuity, relatively spared before 40 and
    significant thereafter.
  phenotype_term:
    preferred_term: Progressive visual loss
    term:
      id: HP:0000529
      label: Progressive visual loss
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A significant decline of BCVA was revealed in patients over 40 years old (P<0.001)."
    explanation: >
      Reports the measured decline in best-corrected visual acuity that this
      phenotype asserts. The previously quoted sentence from this cohort
      ("BCR patients preserved relatively good vision before 40 years old")
      states the opposite of the claim and is retained below only as the
      age qualifier it actually is.
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BCR patients preserved relatively good vision before 40 years old."
    explanation: >
      Qualifies rather than supports the phenotype: it establishes that the
      loss is age-dependent and that vision is comparatively spared in the
      first four decades. Marked PARTIAL because it bounds the claim rather
      than evidencing it.
  - reference: PMID:22497028
    reference_title: "Bietti Crystalline Dystrophy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "With time, loss of peripheral visual field, central acuity, or both result in legal blindness in most if not all affected individuals."
    explanation: >
      Upgrades the frequency justification from a Pattern D clinical estimate to
      a Pattern C mapping: GeneReviews' "most if not all" maps to VERY_FREQUENT
      under docs/frequency-evidence-guidelines.md. Evidence source is OTHER
      because GeneReviews is an expert-curated clinical synthesis.
- category: Ocular
  name: Abnormal Retinal Pigmentation
  description: >
    Pigmentary disturbance of the retinal pigment epithelium accompanying and
    preceding frank atrophy.
  phenotype_term:
    preferred_term: Abnormal retinal pigmentation
    term:
      id: HP:0007703
      label: Abnormal retinal pigmentation
  evidence:
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Cyp4v3 KO mice exhibited progressive retinal degeneration and lipid accumulation, similar to the BCD phenotype, which was exacerbated by a high-fat diet (HFD)."
    explanation: >
      Supports RPE involvement as the site of degeneration underlying the
      pigmentary abnormality.
genetic:
- name: CYP4V2
  association: Biallelic loss-of-function variants
  notes: >
    CYP4V2 encodes a cytochrome P450 fatty acid omega-hydroxylase. The East
    Asian mutational spectrum is dominated by the founder splice-region allele
    c.802-8_810del17insGC, which accounts for 55.7% of disease alleles in a
    Chinese cohort. Genotype affects timing rather than presence of disease:
    compound heterozygotes for the founder allele plus a truncating variant lose
    acuity earlier than founder homozygotes.
  gene_term:
    preferred_term: CYP4V2
    term:
      id: hgnc:23198
      label: CYP4V2
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:37584790
    reference_title: "Clinical and genetic characterization of a large cohort of Chinese patients with Bietti crystalline retinopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Molecular screening detected biallelic CYP4V2 pathogenic variants in 98.3% (172/175) of the families, including 19 novel ones."
    explanation: >
      Establishes CYP4V2 as effectively the sole disease gene, with a diagnostic
      yield near 100% in a large cohort.
treatments:
- name: Iron Chelation (Deferiprone, Preclinical)
  description: >
    Iron chelation targets the ferroptosis arm rather than the enzyme defect.
    Deferiprone suppressed the ferroptotic phenotype in CYP4V2-mutant RPE and,
    given orally, restored retinal function and morphology in Cyp4v3-null mice.
    This is preclinical only - there is no clinical therapy for Bietti
    crystalline dystrophy - but it is recorded because it is a mechanism-directed
    intervention with in vivo rescue, and because it acts on a node distinct
    from the one gene replacement acts on.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: deferiprone
      term:
        id: CHEBI:68554
        label: deferiprone
  target_mechanisms:
  - target: Iron-Dependent Lipid Peroxidation and Ferroptosis
    treatment_effect: INHIBITS
    description: >
      Chelating ferrous iron removes the catalyst of lipid peroxidation, acting
      on the ferroptosis arm specifically and leaving the upstream PUFA
      accumulation untouched.
    evidence:
    - reference: PMID:38992691
      reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "DFP, an iron chelator administration suppressed ferroptosis phenotype in CYP4V2 mutated RPE. Oral administration of DFP also restored the retinal function and morphology in Cyp4v3 KO mice."
      explanation: >
        Demonstrates target engagement in vitro and functional and structural
        rescue in vivo, establishing this node as a druggable target.
  evidence:
  - reference: PMID:38992691
    reference_title: "Uncovering the role of ferroptosis in Bietti crystalline dystrophy and potential therapeutic strategies."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Currently, there is no clinical therapy approach available for BCD patients."
    explanation: >
      States plainly that no clinical therapy exists. Marked PARTIAL because
      this treatment is supported only by preclinical rescue, not by human data.
- name: rAAV-CYP4V2 Gene Replacement (Preclinical)
  description: >
    Recombinant AAV delivery of human CYP4V2 to restore omega-hydroxylase
    activity in the retinal pigment epithelium. Product-development work has
    established a quantitative LC-MS/MS potency assay measuring the enzyme's
    conversion of lauric acid to 12-hydroxylauric acid across AAV2, AAV8 and
    AAV2/8 serotypes - which is the kind of release assay a clinical programme
    requires. No human trial data. The near-monogenic genetics and the founder
    allele make this an unusually tractable gene-replacement target.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: CYP4V2 Loss of Function
    treatment_effect: RESTORES
    description: >
      Vector-delivered CYP4V2 restores the missing omega-hydroxylase, acting on
      the trigger lesion upstream of both downstream arms.
    evidence:
    - reference: PMID:42123783
      reference_title: "Development and Validation of a Quantitative LC-MS/MS Method for Measuring CYP4V2 Enzyme Activity via 12-Hydroxylauric Acid in rAAV-hCYP4V2 Gene Therapy Products."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Gene replacement therapy using rAAV-hCYP4V2 represents a promising therapeutic strategy, requiring robust bioassays for product quality control."
      explanation: >
        Establishes the gene-replacement strategy and that it is at the
        product-characterization stage. Marked PARTIAL because this
        demonstrates restored enzyme activity in transduced cells, not clinical
        benefit.
  evidence:
  - reference: PMID:42123783
    reference_title: "Development and Validation of a Quantitative LC-MS/MS Method for Measuring CYP4V2 Enzyme Activity via 12-Hydroxylauric Acid in rAAV-hCYP4V2 Gene Therapy Products."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "The method was successfully applied to three AAV serotypes (AAV2, AAV8, and AAV2/8), with all RSDs < 23.9%."
    explanation: >
      Documents the potency assay across candidate serotypes. Marked INDIRECT
      because this is manufacturing-stage evidence, not evidence of efficacy.
discussions:
- discussion_id: bcd_ferroptosis_versus_er_stress_dominance
  kind: KNOWLEDGE_GAP
  prompt: >-
    Are ER stress and ferroptosis two independent routes from PUFA overload to
    RPE death in Bietti crystalline dystrophy, or two readouts of one process,
    and which should a non-gene-therapy intervention target?
  attaches_to:
  - "pathophysiology#ER Stress and Mitochondrial Dysfunction"
  - "pathophysiology#Iron-Dependent Lipid Peroxidation and Ferroptosis"
  rationale: >-
    Both arms are supported by rescue experiments in CYP4V2-deficient RPE -
    IRE1-alpha inhibition restores mitochondrial potential and ATP, iron
    chelation suppresses ferroptosis and restores retinal function in vivo - and
    both converge on mitochondrial dysfunction and oxidative stress, so the
    experiments as performed cannot distinguish two parallel routes from one
    route measured two ways. This matters because the arms imply different
    drugs. If they are sequential, only the upstream one is worth targeting; if
    parallel, blocking one leaves the other running, and the single-agent
    rescues reported so far would be hard to explain.
  proposed_experiments:
  - experiment_id: bcd_combined_ire1_iron_epistasis
    name: Epistasis between IRE1-alpha inhibition and iron chelation in CYP4V2-null RPE
    description: >
      Apply IRE1-alpha inhibition and deferiprone alone and in combination to
      CYP4V2-knockout RPE under matched PUFA load, measuring lipid peroxidation,
      ERO1-L-alpha induction, mitochondrial membrane potential and viability. A
      non-additive combination indicates one pathway; additive or synergistic
      rescue indicates two, and identifies which single agent leaves more
      residual death.
references:
- reference: PMID:22497028
  title: Bietti Crystalline Dystrophy.
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

1

PMID:22497028

Bietti Crystalline Dystrophy.

No top-level findings curated for this source.

Bietti Crystalline Dystrophy

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Source YAML

References & Deep Research

References